Rafael Holdings, Inc. - 8-K Filing
Rafael Holdings reports Q4 and FY2026 results with net loss of $9.2M for the quarter and announces FDA NDA submission for remibetadex. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD On October 29, 2026, the Company distributed over a wire service and posted the attached press release (the “Release”) to the i, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $RFL